Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1055/s-0040-1710317 http://scihub22266oqcxt.onion/10.1055/s-0040-1710317 32349133!7295290!32349133     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Thromb+Haemost 2020 ; 120 (6): 949-956 Nephropedia Template TP {{tp|p=32349133|t=2020. Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge |pdf=|usr=}}{{32349133}} gab.com Text Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge JO: Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32349133 #FOAvip The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment. Twit Text FOAVip Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge ????Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32349133 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32349133 #FOAvip English Wikipedia <ref>{{Cite pmid|32349133}}</ref> Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge #MMPMID32349133 Violi F; Pastori D; Cangemi R; Pignatelli P; Loffredo L Thromb Haemost 2020[Jun]; 120 (6): 949-956 PMID32349133show ga The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarction and ischemic stroke. Recent data showed that myocardial injury compatible with coronary ischemia may be detectable in SARS-CoV-2 patients and laboratory data exploring clotting system suggest the presence of a hypercoagulation state. Thus, we performed a systematic review of COVID-19 literature reporting measures of clotting activation to assess if changes are detectable in this setting and their relationship with clinical severity. Furthermore, we discussed the biologic plausibility of the thrombotic risk in SARS-CoV-2 and the potential use of an antithrombotic treatment. |Algorithms[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Cardiology[MESH] |Coronavirus Infections/blood/*complications[MESH] |Fibrin Fibrinogen Degradation Products/analysis[MESH] |Fibrinolytic Agents/*therapeutic use[MESH] |Humans[MESH] |Liver Failure/therapy[MESH] |Pandemics[MESH] |Partial Thromboplastin Time[MESH] |Platelet Count[MESH] |Pneumonia, Viral/blood/*complications[MESH] |Prothrombin Time[MESH] |Risk[MESH] |SARS-CoV-2[MESH] |Thrombophilia/*prevention & control/*therapy[MESH] |Thrombosis/*prevention & control/*therapy[MESH]Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A N(epmc).pdf DeepDyve Pubget Overpricing